Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1945 1
1948 1
1949 2
1950 1
1952 2
1953 4
1954 6
1955 6
1956 3
1957 6
1958 4
1959 4
1960 7
1961 8
1962 9
1963 3
1964 6
1965 12
1966 9
1967 3
1968 2
1969 11
1970 9
1971 4
1972 6
1973 5
1974 5
1975 6
1976 5
1977 7
1978 6
1979 2
1980 4
1981 4
1982 5
1983 7
1984 4
1985 6
1986 5
1987 13
1988 9
1989 5
1990 20
1991 21
1992 17
1993 12
1994 22
1995 12
1996 19
1997 19
1998 15
1999 24
2000 25
2001 24
2002 34
2003 25
2004 32
2005 28
2006 32
2007 23
2008 31
2009 30
2010 19
2011 21
2012 19
2013 38
2014 21
2015 34
2016 35
2017 35
2018 44
2019 36
2020 41
2021 44
2022 50
2023 27
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

1,090 results

Results by year

Filters applied: . Clear all
Page 1
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, Baron A, Park JW, Han G, Jassem J, Blanc JF, Vogel A, Komov D, Evans TRJ, Lopez C, Dutcus C, Guo M, Saito K, Kraljevic S, Tamai T, Ren M, Cheng AL. Kudo M, et al. Among authors: baron a. Lancet. 2018 Mar 24;391(10126):1163-1173. doi: 10.1016/S0140-6736(18)30207-1. Lancet. 2018. PMID: 29433850 Free article. Clinical Trial.
Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma.
Finn RS, Ikeda M, Zhu AX, Sung MW, Baron AD, Kudo M, Okusaka T, Kobayashi M, Kumada H, Kaneko S, Pracht M, Mamontov K, Meyer T, Kubota T, Dutcus CE, Saito K, Siegel AB, Dubrovsky L, Mody K, Llovet JM. Finn RS, et al. Among authors: baron ad. J Clin Oncol. 2020 Sep 10;38(26):2960-2970. doi: 10.1200/JCO.20.00808. Epub 2020 Jul 27. J Clin Oncol. 2020. PMID: 32716739 Free PMC article. Clinical Trial.
Authors' Response.
Hirsch EA, Barón AE, Risendal B, Studts JL, New ML, Malkoski SP. Hirsch EA, et al. Among authors: baron ae. J Am Coll Radiol. 2022 Mar;19(3):404-405. doi: 10.1016/j.jacr.2021.11.018. Epub 2022 Feb 8. J Am Coll Radiol. 2022. PMID: 35143785 No abstract available.
Pulmonary vascular resistance and clinical outcomes in patients with pulmonary hypertension: a retrospective cohort study.
Maron BA, Brittain EL, Hess E, Waldo SW, Barón AE, Huang S, Goldstein RH, Assad T, Wertheim BM, Alba GA, Leopold JA, Olschewski H, Galiè N, Simonneau G, Kovacs G, Tedford RJ, Humbert M, Choudhary G. Maron BA, et al. Among authors: baron ae. Lancet Respir Med. 2020 Sep;8(9):873-884. doi: 10.1016/S2213-2600(20)30317-9. Epub 2020 Jul 27. Lancet Respir Med. 2020. PMID: 32730752 Free PMC article.
Acute cholecystitis: early versus delayed cholecystectomy, a multicenter randomized trial (ACDC study, NCT00447304).
Gutt CN, Encke J, Köninger J, Harnoss JC, Weigand K, Kipfmüller K, Schunter O, Götze T, Golling MT, Menges M, Klar E, Feilhauer K, Zoller WG, Ridwelski K, Ackmann S, Baron A, Schön MR, Seitz HK, Daniel D, Stremmel W, Büchler MW. Gutt CN, et al. Among authors: baron a. Ann Surg. 2013 Sep;258(3):385-93. doi: 10.1097/SLA.0b013e3182a1599b. Ann Surg. 2013. PMID: 24022431 Clinical Trial.
Single-plasmon interferences.
Dheur MC, Devaux E, Ebbesen TW, Baron A, Rodier JC, Hugonin JP, Lalanne P, Greffet JJ, Messin G, Marquier F. Dheur MC, et al. Among authors: baron a. Sci Adv. 2016 Mar 11;2(3):e1501574. doi: 10.1126/sciadv.1501574. eCollection 2016 Mar. Sci Adv. 2016. PMID: 26998521 Free PMC article.
Autoimmune swallowing disorders.
Amos J, Baron A, Rubin AD. Amos J, et al. Among authors: baron a. Curr Opin Otolaryngol Head Neck Surg. 2016 Dec;24(6):483-488. doi: 10.1097/MOO.0000000000000312. Curr Opin Otolaryngol Head Neck Surg. 2016. PMID: 27585081 Review.
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial.
Sharma P, Retz M, Siefker-Radtke A, Baron A, Necchi A, Bedke J, Plimack ER, Vaena D, Grimm MO, Bracarda S, Arranz JÁ, Pal S, Ohyama C, Saci A, Qu X, Lambert A, Krishnan S, Azrilevich A, Galsky MD. Sharma P, et al. Among authors: baron a. Lancet Oncol. 2017 Mar;18(3):312-322. doi: 10.1016/S1470-2045(17)30065-7. Epub 2017 Jan 26. Lancet Oncol. 2017. PMID: 28131785 Clinical Trial.
Migraine and Two-Pore-Domain Potassium Channels.
Verkest C, Häfner S, Ávalos Prado P, Baron A, Sandoz G. Verkest C, et al. Among authors: baron a. Neuroscientist. 2021 Jun;27(3):268-284. doi: 10.1177/1073858420940949. Epub 2020 Jul 27. Neuroscientist. 2021. PMID: 32715910 Review.
1,090 results